Recombinant Human EGF (Epidermal Growth Factor)

Cat.No.:

CYT-P01133

Product Background

Human Epidermal Growth Factor

Epidermal Growth Factor (EGF) was originally discovered in crude preparations of nerve growth factor prepared from mouse submaxillary glands as an activity that induced early eyelid opening, incisor eruption, hair growth inhibition, and stunting of growth when injected into newborn mice. Human EGF was isolated from urine based on its inhibitory effect on gastric secretion and named urogastrone, accordingly. EGF is prototypic of a family of growth factors that are derived from membrane-anchored precursors. All members of this family are characterized by the presence of at least one EGF structural unit (defined by the presence of a conserved 6 cysteine motif that forms three disulfide bonds) in their extracellular domain. EGF is initially synthesized as a 130 kDa precursor transmembrane protein containing 9 EGF units. The mature soluble EGF sequence corresponds to the EGF unit located proximal to the transmembrane domain. The membrane EGF precursor is capable of binding to the EGF receptor and was reported to be biologically active. Mature human EGF shares 70 % a.a. sequence identity with mature mouse and rat EGF.

Product Information

Source

Escherichia coli.

Molecular Weight

Approximately 6.2 kDa, a single non-glycosylated polypeptide chain containing 53 amino acids.

AA Sequence

NSDSECPLSH DGYCLHDGVC MYIEALDKYA CNCVVGYIGE RCQYRDLKWW ELR

Biological Activity

Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation
assay using murine Balb/c 3T3 cells is less than 1 ng/ml, corresponding to a specific activity of > 1.0
¡Á10⁶IU/mg.

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation

Lyophilized from a 0.2 mm filtered concentrated solution in PBS, pH 7.4.

Endotoxin

Less than 1 EU/mg of rHuEGF as determined by LAL method.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a
concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and
stored at ¡Ü -20 ¡ãC. Further dilutions should be made in appropriate buffered solutions.

Purity

> 95 % by SDS-PAGE and HPLC analyses.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 ¡ãC as supplied.

1 month, 2 to 8 ¡ãC under sterile conditions after reconstitution.

3 months, -20 to -70 ¡ãC under sterile conditions after reconstitution.

Usage Information

This  product  is  offered  by  BioCytoSci only  for Scientific Research & Laboratory  USE. NOT FOR OTHER USE.

Order Information

Cata.No.

Quantity

Price($)

Price($)

Availability

CYT-P01133

100ug

$156.00

€171.60

In stock

CYT-P01133

500ug

$980.00

€1,078.00

In stock

CYT-P01133

1000ug

$4,200.00

€4,620.00

In stock

Free Delivery on orders over $200.00.

We Devoted Ourselves To The Development Of Biomedical Research Reagent.